• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Absci Corporation (Amendment)

    2/14/24 9:42:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    SC 13G/A 1 d780767dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Absci Corporation

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    00091E109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00091E109       Page 2 of 6 Pages

     

     1   

     NAME OF REPORTING PERSONS

     

     Phoenix Venture Partners II, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     14,379,522

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     14,379,522

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     14,379,522

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     15.5%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     PN

     


    CUSIP No. 00091E109       Page 3 of 6 Pages

     

     1   

     NAME OF REPORTING PERSONS

     

     Phoenix General Partner II LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     14,379,5221

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     14,379,522

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     14,379,522

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     15.5%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

     

    1 

    Shares reported in this table are held by Phoenix Venture Partners II, LP, of which the Reporting Person is the sole general partner.


    CUSIP No. 00091E109       Page 4 of 6 Pages

     

    ITEM 1 (a).

    NAME OF ISSUER

    Absci Corporation (the “Issuer”)

     

    ITEM 1 (b).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    18105 SE Mill Plain Blvd

    Vancouver, WA 98683

     

    ITEM 2 (a).

    NAME OF PERSONS FILING

    This joint statement on Schedule 13G is being filed by Phoenix General Partner II LLC, a Delaware limited liability company (the “General Partner”), and Phoenix Venture Partners II, LP, a Delaware limited partnership (the “Fund” and, together with the General Partner, the “Reporting Persons”).

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    ITEM 2 (b).

    ADDRESS OF PRINCIPAL BUSINESS OFFICE

    The business address of each of the Reporting Persons is 1700 El Camino Real, Suite 355, San Mateo, CA 94402.

     

    ITEM 2 (c).

    CITIZENSHIP

    The Fund is a Delaware limited partnership; and the General Partner is a Delaware limited liability company.

     

    ITEM 2 (d).

    TITLE OF CLASS OF SECURITIES

    Common stock, par value $0.0001 per share (the “Common Stock”).

     

    ITEM 2 (e).

    CUSIP NUMBER

    00091E109

     

    ITEM 3.

    Not Applicable.

     

    ITEM 4.

    OWNERSHIP

     

      (a)

    Amount beneficially owned by each Reporting Person: 14,379,522 shares of Common Stock.

     

      (b)

    Percent of class beneficially owned by each Reporting Person: 15.5%.

     

      (c)

    Number of shares as to which each of the Fund and the General Partner has (i) the sole power to vote or direct the vote of: 14,379,522, (ii) the shared power to vote or to direct the vote of: 0, (iii) the sole power to dispose or to direct the disposal of: 14,379,522, and (iv) the shared power to dispose or to direct the disposal of: 0.


    CUSIP No. 00091E109       Page 5 of 6 Pages

     

    The percentages of beneficial ownership reported herein, and on each Reporting Person’s cover page to this Schedule 13G, are based on a total of 92,938,477 shares of Common Stock issued and outstanding as of October 31, 2023, as reported in the most recent quarterly report of the Issuer on Form 10-Q for its fiscal quarter ended September 30, 2023.

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    Not applicable.

     

    ITEM 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

    Not applicable.

     

    ITEM 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

    Not applicable.

     

    ITEM 9.

    NOTICE OF DISSOLUTION OF GROUP

    Not applicable.

     

    ITEM 10.

    CERTIFICATION

    Not applicable.


    CUSIP No. 00091E109       Page 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE: February 14, 2024
    PHOENIX VENTURE PARTNERS II, LP
    By:   Phoenix General Partner II LLC,
      its General Partner
    By:   /s/ John Chen
      John Chen
      Managing Member
    PHOENIX GENERAL PARTNER II LLC
    By:   /s/ John Chen
      John Chen
      Managing Member
    Get the next $ABSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    5/4/2023$4.00Buy
    H.C. Wainwright
    8/12/2022Overweight → Underweight
    JP Morgan
    7/18/2022$8.00Buy
    Truist
    More analyst ratings

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Redmile Group, Llc bought $999,999 worth of shares (222,222 units at $4.50) (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/5/24 9:30:43 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Absci Corporation with a new price target

      Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

      1/22/25 7:30:02 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Guggenheim initiated coverage on Absci Corporation with a new price target

      Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00

      10/2/24 7:13:36 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Morgan Stanley initiated coverage on Absci Corporation with a new price target

      Morgan Stanley initiated coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

      7/3/24 7:24:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Walker Shelby J. was granted 59,300 shares (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:43:06 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SVP, CAO Bedrick Todd was granted 29,700 shares, increasing direct ownership by 22% to 167,827 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:42:16 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chief Executive Officer Mcclain Sean was granted 190,200 shares, increasing direct ownership by 2% to 8,384,621 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:41:15 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Financials

    Live finance-specific insights

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

      VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available fo

      3/4/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Participate in Upcoming Investor Conferences

      VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time 24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time Interested parties may access live and archived webcasts of the fireside chat sessions on the company's

      3/26/25 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation

      SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)

      5/12/25 10:24:40 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Absci Corporation

      SCHEDULE 13D/A - Absci Corp (0001672688) (Subject)

      4/29/25 9:31:04 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by Absci Corporation

      DEFA14A - Absci Corp (0001672688) (Filer)

      4/28/25 4:13:02 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Absci Corporation

      SC 13G - Absci Corp (0001672688) (Subject)

      11/14/24 4:02:50 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Absci Corporation

      SC 13G/A - Absci Corp (0001672688) (Subject)

      11/12/24 9:50:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Absci Corporation (Amendment)

      SC 13D/A - Absci Corp (0001672688) (Subject)

      3/5/24 5:15:30 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

      Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

      1/10/24 7:30:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

      VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a

      6/6/23 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Welcomes Meta Senior Executive to Board of Directors

      VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the newest member of its Board of Directors. With three decades of leadership in scaling technologies, innovating business models and growing companies, Mr. Rabinovitsj will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster. "Absci has impressed me with their technology and data, together which have the potential to turn Absci's bold vision into reality: to create therapeutics at a

      11/2/22 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care